Cohance Lifesciences Limited
Cohance Lifesciences Limited
Pharmaceuticals/Clinical Research
Member Since, Aug 02, 2025
Hyderabad, Telangana; registered office in Mumbai
Add to Favourite Report Abuse

About Company

Company Name
Cohance Lifesciences Limited 
Company Summary
Cohance Lifesciences (formerly Suven Pharmaceuticals until May 2025) is an integrated, global CDMO (contract development and manufacturing organization) and API manufacturing platform headquartered in Hyderabad, India. The firm provides end-to-end services across molecule lifecycles, including complex CDMO projects, APIs and formulation manufacturing, clinical and analytical services, and specialty chemicals such as electronic-grade chemicals and ADCs (antibody‑drug conjugates). It serves customers in nearly 60 countries, offering over 80 molecules backed by R&D and backward-integration capabilities 
CEO
Dr. V. Prasada Raju – Managing Director & CEO, in position since March 10, 2021. He has over 28 years of techno-commercial experience at Granules India and Dr. Reddy’s Laboratories with a Ph.D. in chemistry and post‑graduate diploma in patents law
(Note: there is recent corporate-level reporting that Dr. Sudhir Kumar Singh, previously in charge of the CDMO business, resigned from the CEO position effective July 31, 2025, with appointment of Yann D’Herve for the CDMO segment. However, corporate governance information still identifies Dr. Prasada Raju as the overall Managing Director & CEO — as confirmed on the company’s board page) 
Industry
Pharmaceuticals – Specialty & Generic Drug Manufacturing, with CDMO, API, formulation and chemical service operations 
Ownership Type
Privately held; a subsidiary of Advent International, the private equity firm that wholly owns Cohance and controls merged operations with Suven Pharma . In regulatory filings, promoter ownership stands at ~99.97% 
Company Details

  • Former Name: Suven Pharmaceuticals Limited (rebranded to Cohance Lifesciences in May 2025) 

  • Business Units: CDMO services, API & formulation manufacturing, clinical & analytical service division (“CR‑Bio”), specialty chemicals including ADC platform Merger Activity: Suven Pharma and Cohance merged in early 2024 as part of a strategy to build a global CDMO platform; Advent holds ~66.7% of the combined entity, with 33.3% public shareholders following the all‑share swap deal 

Headquarters & Location

  • Primary Location: Hyderabad, Telangana, India

  • Registered Address(es):
    • Galaxy by Aurobindo Realty, Sy No 83/1, Raidurg, Hyderabad 500081 
    • Registered address in Mumbai: 215 Atrium, C‑Wing, 8th Floor, 819‑821 Andheri Kurla Road, Andheri East, Mumbai 400093 

Number of Employees
Approximately 1,193 employees (as of latest data) 
Established
Founded originally as Suven Pharmaceuticals in 1989; legally incorporated as Cohance Lifesciences in July 2020, with a renaming to Cohance in May 2025

Company Detail

  • verified
    Verified Yes
  • group
    Company Size 1193
  • cake
    Founded In 1989
  • corporate_fare
    Organization Type Private
  • corporate_fare
    Total Offices 14
  • cases
    Opend Jobs 0

Current Openings

Quick Links
Jobs By Functional Area
Jobs By Industry
Contact Us
Copyright © 2026 Roji Roty. All Rights Reserved.